耐火材料(行星科学)
移植
化疗
造血干细胞移植
挽救疗法
淋巴瘤
布仑妥昔单抗维多汀
环磷酰胺
美罗华
外科
养生
作者
Gonzalo Bentolila,Astrid Pavlovsky
标识
DOI:10.1080/10428194.2020.1732959
摘要
The treatment of classic Hodgkin lymphoma (HL) is a success in onco-hematology. Despite the high cure rate of HL with initial therapy, 5-10% of patients are primary refractory and 10-20% will eventually relapse. The standard treatment for these patients is salvage chemotherapy and autologous stem cell transplantation (ASCT). Only about half of these patients will benefit from this procedure. The prognosis of relapsed refractory (rr) HL has improved with the introduction of effective drugs. With these options available, identification of reliable risk factors is important to guide treatment over the course of disease. Different variables including performance status, anemia, B symptoms, laboratory abnormalities, treatment intensity before ASCT, response to therapy, and duration of remission, have been analyzed to determine risk for progression-free survival (PFS) and overall survival (OS) after ASCT. This review will discuss the publications analyzing these factors, the validated risk scores useful to identify patients at high risk of progression after ASCT, and will describe future perspectives.
科研通智能强力驱动
Strongly Powered by AbleSci AI